Related Experiment Video
Updated: Jun 29, 2026
A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
Published on: April 17, 2019
PET imaging in neuroendocrine tumors: current status and future prospects
1Division of Nuclear Medicine, Hospital of University of Pennsylvania, Spruce Street, Philadelphia, PA 19194, USA.
Abstract:
Neuroendocrine tumors (NET) are relatively rare diverse group of tumors that possess several unique characteristics and occur most commonly in the gastrointestinal tract. An important feature of these tumors is that they express somatostatin (SST) receptors, and thus can be successfully targeted with specific radiolabeled SST receptor related compounds. This has led to the introduction of multitude of single photon emission computed tomography (SPECT) and positron emission tomography (PET) tracers, which have significantly improved the ability for imaging these neoplastic lesions with high spatial resolution in the abdomen and elsewhere in the body. The introduction of Gallium-68 labeled radiopharmaceuticals as viable PET agents have added a new dimension to the management of patients with NET by providing high quality images compared with planar or SPECT with single photon emitting preparations. (18)F-labeled DOPA has demonstrated impressive results in differentiating between focal and diffuse disease in hyperinsulinism of the newborn which appears to be of crucial clinical benefit and has altered the management of these patients significantly. With regard to other types of NET, the current experience with such agents is relatively limited and therefore prospective studies are required to further define the role of PET in this complicated group of patients.
Insights
Radiolabeled somatostatin receptor targeted compounds, including Gallium-68 PET agents, significantly improve imaging for neuroendocrine tumors (NET). (18)F-labeled DOPA shows promise for specific conditions, but further studies are needed for broader NET applications.
Area of Science:
- Nuclear medicine
- Oncology
- Radiopharmaceutical science
Background:
- Neuroendocrine tumors (NET) are rare, diverse gastrointestinal malignancies.
- NETs characteristically express somatostatin (SST) receptors.
- SST receptor targeting enables diagnostic and therapeutic strategies.
Purpose of the Study:
- To review the role of somatostatin receptor targeted radiopharmaceuticals in neuroendocrine tumor imaging.
- To highlight advancements in single photon emission computed tomography (SPECT) and positron emission tomography (PET) tracers for NET detection.
- To discuss the clinical impact of Gallium-68 and Fluorine-18 labeled agents.
Main Methods:
- Review of current literature on radiolabeled somatostatin receptor targeted compounds for NET imaging.
- Analysis of SPECT and PET tracers, including Gallium-68 and (18)F-labeled DOPA.
- Evaluation of imaging performance and clinical utility in various NET contexts.
Main Results:
- SPECT and PET tracers targeting SST receptors have enhanced the spatial resolution and accuracy of NET lesion detection.
- Gallium-68 labeled radiopharmaceuticals offer high-quality PET imaging for NET management.
- (18)F-labeled DOPA demonstrates significant clinical benefit in specific conditions like hyperinsulinism of the newborn.
Conclusions:
- Radiolabeled SST receptor targeted compounds represent a major advancement in NET imaging.
- PET imaging, particularly with Gallium-68 agents, provides superior visualization of NETs.
- Further prospective studies are essential to fully define the role of these advanced imaging agents across the spectrum of NETs.
Related Concept Videos
01:29Positron Emission Tomography
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body being...
01:25Imaging Studies II: Positron Emission Tomography and Scintigraphy
Fundamental Principles of PET